readthroughSign in
CompanyONCYNasdaqSan Diego, CA

Oncolytics Biotech

Oncolytics Biotech develops pelareorep, an intravenously delivered double-stranded RNA immunotherapeutic in clinical trials for pancreatic, breast, colorectal, and anal cancers, primarily in combination with chemotherapy or checkpoint inhibitors.

10-QNov 13Latest SEC filing
Nov 16Latest story